1. Medtech Insight
  2. >>Business
  3. >>R&D

Gottlieb Points To Breakthrough And Localized Therapy Devices For Non-Opioid Pain Control

 
• By Sue Darcey

In one of his last public appearances as US FDA commissioner, Scott Gottlieb identified new opioid-alternative medtech products in the regulatory pipeline that provide distraction therapy and thermal management for pain relief. The agency chief also pointed to old-school devices that provide localized delivery of analgesic drugs as effective opioid-substitute or opioid-reducing devices.

Avanos-OnQ-Pump
The Avanos Medical On-Q Pump with OnDemand is one of many opioid-sparing pain pump devices for pain control

Outgoing US FDA Chief Gottlieb says there are several medtech products that could serve as alternatives to opioids to reduce or control pain, including implantable pumps designed for local delivery of analgesics, as well as products that were designated as breakthrough pain-control devices by the agency in a 2018 “FDA Innovation Challenge."

 “I think there are a lot of places for new innovation,” Gottlieb said at a March 29 “Alliance for a Stronger FDA” event in Washington, DC. The meeting was billed as one of the FDA commissioner’s last public appearances before he leaves the agency in mid-April

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By Marion Webb

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

SpotitEarly Raised $20.3M In New Funding To Bring AI- And Dog-Sniffing-Powered Early Cancer Detection Test To US

 
• By Marion Webb

Israeli-based SpotitEarly hopes to bring an early cancer-detection test, which uses dogs’ noses to detect compounds in exhaled breath and AI analysis, to US homes in 2026.

More from Business

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By Marion Webb

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

SpotitEarly Raised $20.3M In New Funding To Bring AI- And Dog-Sniffing-Powered Early Cancer Detection Test To US

 
• By Marion Webb

Israeli-based SpotitEarly hopes to bring an early cancer-detection test, which uses dogs’ noses to detect compounds in exhaled breath and AI analysis, to US homes in 2026.